Possible Biomarkers for Cancer Immunotherapy
AbstractImmune checkpoint inhibitors (ICIs) have drastically changed the clinical care of cancer. Although cancer immunotherapy has shown promise in various types of malignancies, thus far, the proportion of patients who can benefit from ICIs is relatively small. Immune-related adverse events and high cost are unavoidable problems. Therefore, biomarkers defining patients that are most likely to benefit from ICIs are urgently needed. The expression of programmed cell death-ligand 1 (PD-L1) is a logical biomarker for the prediction of response to anti-PD1/PD-L1 immunotherapies. However, its usefulness is currently debatable because of its varied definition, threshold, and spatial/temporal heterogeneity. Recently, it was reported that the tumor mutational burden, expression of neoantigens, mismatch repair status, and specific gene mutations may be markers for the success of treatment with ICIs. Moreover, it was suggested that the fecal microbiota prior to immunotherapy may play an important role in predicting the efficacy of ICIs. In this review, we focused on these potential biomarkers for cancer immunotherapy reported in recent clinical articles. Further studies are warranted to develop a predictive model using these biomarkers, with the aim of practicing precision medicine in cancer immunotherapy. View Full-Text
Share & Cite This Article
Otoshi, T.; Nagano, T.; Tachihara, M.; Nishimura, Y. Possible Biomarkers for Cancer Immunotherapy. Cancers 2019, 11, 935.
Otoshi T, Nagano T, Tachihara M, Nishimura Y. Possible Biomarkers for Cancer Immunotherapy. Cancers. 2019; 11(7):935.Chicago/Turabian Style
Otoshi, Takehiro; Nagano, Tatsuya; Tachihara, Motoko; Nishimura, Yoshihiro. 2019. "Possible Biomarkers for Cancer Immunotherapy." Cancers 11, no. 7: 935.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.